Remote ischemic conditioning (RIC) is a means of playing the systemic organ protective effect by transient ischemia/reperfusion of the limb,thus reduces the damage caused by more severe ischemic events.RIC can be applied before,during and after ischemic events;among them,the application before ische-mia is relatively more,which is called the remote ischemic preconditioning (RIPC).Researches have shown that RIC has considerable clinical translation value characterizing by non-invasion,economy,safety and effect. Although the specific mechanism needs to continue to be explored,but its protective targets are quite exten-sive.Especially for the heart,RIC seems to have favorable protective effects on the heart under almost all pathological conditions.Moreover,RIC has a certain degree of protective effect on the nervous system,lungs,livers and kidneys.Based on this,this article reviews the protective effects of RIC in different organs and its possible mechanisms.

Objective To observe the effect of Shenmai injection combined concurrent chemoradiotherapy on immune function in patients with locally advanced non-small cell lung cancer.Methods A total of 80 patients with locally advanced non-small cell lung cancer were randomly divided into treatment group and control group.In treatment group,40 patients received simultaneous three-dimensional conformal radiotherapy combined with TP(docetaxel+cisplatin)chemotherapy,while given Shenmai injection in the process of concurrent chemoradiotherapy.In control group,40 patients only received chemoradiotherapy.The changes of T cell subsets were observed between the two groups.Results It showed no significant differences in percentages of CD+3,CD+4,CD+16CD+56and CD+4/CD+8 ratio between two groups pre-treatment(all P＞0.05).There were no significant adverse reactions occurred after received Shenmai injection in treatment group.Conclusion It play an important role in improving immune function of patients with locally advanced non-small cell lung cancer who received Shenmai injection combined concurrent chemoradiotherapy.